Bill
HR 4752
Overview: HR 4752, also known as the Reducing Hereditary Cancer Act, is a federal bill introduced in the U.S. House of Representatives.Purpose and Intent: The main goal of the Redu
Overview: HR 4752, also known as the Reducing Hereditary Cancer Act, is a federal bill introduced in the U.S. House of Representatives.
Purpose and Intent: The main goal of the Reducing Hereditary Cancer Act is to improve access to genetic testing and counseling services for individuals at risk of developing hereditary cancers. The bill aims to address disparities in access to these services and promote early detection and prevention of certain types of cancer.
Key Provisions:
- Requires health insurance plans to cover the cost of genetic testing and counseling for individuals with a family history of hereditary cancers
- Establishes a grant program to support the development and expansion of hereditary cancer screening and prevention programs
- Directs the Centers for Disease Control and Prevention (CDC) to conduct public awareness campaigns about the importance of genetic testing and counseling
Affected Parties and Impacts: The primary beneficiaries of the Reducing Hereditary Cancer Act are individuals with a family history of hereditary cancers, who may gain improved access to genetic testing and counseling services. Healthcare providers, particularly those specializing in oncology and genetics, may also benefit from increased utilization of these services and the potential for earlier cancer detection and prevention.
Procedural and Timeline Considerations: HR 4752 was introduced in the U.S. House of Representatives in July 2025 and is currently in the early stages of the legislative process. The bill will need to undergo committee hearings, potential amendments, and floor votes in both the House and Senate before it can be signed into law.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
